Arthritis Therapeutics Market

Arthritis Therapeutics Market (Type: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Gout, and Others; Drug Class: TNF Inhibitors, Interleukin Inhibitors, NSAIDs, Corticosteroids, Xanthine Oxidase Inhibitors, and Others; Route of Administration: Oral, Parenteral, and Topical; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Arthritis Therapeutics Market: Numerous Product and Novel Drug Launches Leading to New Heights

The arthritis therapeutics market, characterized by healthy growth, is witnessing numerous promising pipeline projects and new product launches in parallel to increasing awareness campaigns run by public and private organizations. The patent expiration of blockbuster drugs is putting more pressure on manufacturers to develop effective versions of these drugs, which is projected to pave the way for the advancements of biosimilar products.

According to the Centers for Disease Control and Prevention (CDC) data published in 2018, ~54 Mn adults in the U.S. have been diagnosed with arthritis, and the number will grow to ~78 Mn by 2040. In this fast-paced era, individuals can’t afford to reduce their range of motion, which pertinently entails that those residing in developed countries are massively partaking in the diagnosis and treatment of arthritis as compared to those in developing countries. In the future, as the success of health awareness campaigns increases in developing countries, manufacturers in the arthritis therapeutics market will scramble towards these countries to leverage the first mover’s advantage.

arthritis therapeutics market infographic

Perpetual Increase in Drug Prices to Impact Health of Arthritis Therapeutics Market

Despite the stronghold of disease-modifying antirheumatic drugs (DMARDs) in the arthritis therapeutics market, next gen antibody therapeutics are found to gain ground in recent times, on account of their higher efficiency. However, the efficiency of these drugs comes at a price, indeed a high one, ranging from US$ 1,000 to US$ 3,000 per month, which could hold back the sales potential of these drugs.

The price of Humira - a default drug for the treatment of arthritis - saw a steep increase in its price by 68.7% over the last five years, which equals to US$ 3,700 for a month-long supply. Also, the wholesale cost of the drug Enbrel has risen by 80.3% in the same time period, as found by Alliance of Community Health Plans. What’s more of an adoption concern for patients is the lack of discounts and deals, and the retail price further rises when they are distributed to retailers and pharmacies. Given the recommendation for a long-term course of arthritis treatment, high cost can affect the monthly budgets of patients, which could negatively impact sales in the arthritis therapeutics market space.

Parenteral Route to Grow as Preferable Drug-consumption Mode

As per the report, in 2019, the parenteral route of drug administration is projected to be used for ~83% cases for arthritis treatment, while in the remaining ~17% cases, the oral and topical route will be preferred. To put this data into perspective, parenteral administration possesses better control over the dose and frequency, thereby ensuring an improved treatment outcome as compared to oral therapeutics. These routes of drug administration, in turn, are also found to offer better bioavailability and metabolism avoidance. On the contrary, patients are liable to maintain a course of oral drugs on their own, and in cases where they miss out on popping a pill, recovery can take a longer time.

arthritis therapeutics market segmentation

Analysts’ Opinion on Arthritis Therapeutics Market

Analysts of the report opine that, the arthritis therapeutics market will record 8.5% more sales in 2019 over 2018, and continue to advance at a CAGR of ~6% during 2019-2027. The high prevalence of arthritis that primarily weakens the joints and degrades the quality of life of patients, is projected to encourage more patients to avail proper treatment options. Given the growing demand, head-to-head trails to boost the efficacy profiles of drugs intensify the competition in the arthritis therapeutics market, and strategic partnership to target new markets backed by innovative product-level approaches will form a profitable deal for manufacturers.

It is worth noting that, retail pharmacies will take over ~78% sales of these therapeutics in the year 2019, which implies the need for market players to strengthen distribution partnerships with retailers of all scales.

Global Arthritis Therapeutics Market: Overview

  • The global arthritis therapeutics market was valued at ~US$ 43 Bn in 2018, and is projected to expand at a CAGR of ~6% from 2019 to 2027, to reach ~US$ 72.6 Bn by 2027.
  • Increasing incidence of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and other types of arthritis across the globe, is a major factor that is likely to fuel the global arthritis therapeutics market.
  • Ongoing arthritis clinical trials, increase in the geriatric population, rising investments in research & development, increasing demand for biologics, launching of novel products, and surge in mergers and strategic alliances are also anticipated to propel the growth of the global market.
  • Arthritis is an inflammatory joint condition, which causes pain and stiffness, and worsens with age. More than 100 types of arthritis exists, along with different causes and underlying infections. The common types of arthritis are rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
  • Several therapeutics and medications have been developed in recent years to relieve and treat the symptoms of arthritis. The most commonly used drugs belong to the drug class of TNF inhibitors, interleukin inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other drugs. TNF inhibitors are widely utilized for the treatment of arthritis disorders. Arthritis is a highly underdiagnosed and undertreated medical condition, with a large number of patients unsatisfied with the current treatment options available. This offers significant opportunity to biopharmaceutical players operating in the arthritis therapeutics market to offer novel drugs. The under-penetration of biologic drugs in a majority of developed and emerging markets for the treatment of arthritis offers significant opportunities to global biopharmaceutical players.
  • A large number of both, small molecules and biologic products are under different phases of clinical trials. Leading companies have made significant investments in clinical R&D, and have established strategic partnerships and collaborations to accelerate new product development.

Global Arthritis Therapeutics Market: Key Segment

  • Based on type, the global arthritis therapeutics market has been categorized into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and others. Among these, the rheumatoid arthritis segment is the largest, and is expected to dominate the market during the forecast period. The high market share of the rheumatoid arthritis segment can be attributed to the availability of effective biologics for its treatment. The psoriatic arthritis segment is projected to grow at the highest pace during the forecast period, due to increasing number of psoriasis patients likely to develop psoriatic arthritis.
  • In terms of drug class, the global arthritis therapeutics market has been divided into TNF inhibitors, interleukin inhibitors, NSAIDs, corticosteroids, xanthine oxidase inhibitors, and others. The TNF inhibitors segment dominates the global market, owing to its higher efficacy rate as compared to other small molecules. Moreover, increasing investments toward the development of TNF inhibitor biologics are likely to drive the segment. The interleukin inhibitors segment is expected to expand at the highest CAGR, owing to ongoing clinical studies supporting their effectiveness, and quick adoption of interleukin inhibitors in gout, PsA, and RA indications.
  • On the basis of route of administration, the global arthritis therapeutics market has been segmented into oral, parenteral, and topical. The parenteral segment accounted for the largest share of the global market, and is expected to continue its dominance, owing to large volume prescriptions of biologic drugs administered through intravenous and subcutaneous injections.
  • Based on distribution channel, the global market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment holds a major market share, owing to the easy availability of biologics drugs in retail pharmacies, and increasing retail pharmacy stores across the globe.

Global Arthritis Therapeutics Market: Major Players

  • Key players operating in the global arthritis therapeutics market include
    • Novartis AG
    • Eli Lilly and Company
    • Amgen Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Pfizer Inc
    • Janssen Global Services
    • LLC (Johnson & Johnson)
    • F. Hoffmann-La Roche Ltd
    • Sanofi.
  • These players are focused on mergers & acquisitions, development of novel products, launch of biosimilars, and implementation of inorganic and inorganic growth strategies to strengthen their product portfolios and global footprint.
  • Moreover, companies are attracting investments for the research & development of arthritis drugs in order to improve patient care and remain competitive in the global market.

Global Arthritis Therapeutics Market – Segmentation 

Type

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Gout
  • Others

Drug Class

  • TNF Inhibitors
  • Interleukin Inhibitors
  • NSAIDs
  • Corticosteroids
  • Xanthine Oxidase Inhibitors
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North
  • America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of arthritis therapeutics market?

Arthritis therapeutics market to reach ~US$ 72.6 Bn by 2027

What is the anticipated CAGR of the arthritis therapeutics market in the forecast period?

Arthritis therapeutics market is projected to expand at a CAGR of ~6% from 2019 to 2027

What are the key driving factors for the growth of the arthritis therapeutics market?

Arthritis therapeutics market is driven by increasing incidence of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and other types of arthritis across the globe

Which is the rising prominent segment in the arthritis therapeutics market?

The rheumatoid arthritis segment is the largest, and is expected to dominate the market during the forecast period

Who are the key players in the arthritis therapeutics market?

Key players in the global arthritis therapeutics market include Novartis AG, Eli Lilly and Company, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4.  Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Arthritis Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Arthritis Therapeutics Market Analysis and Forecast, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key product/brand Analysis

        5.2. Pipeline Analysis

        5.3. Disease Prevalence & Incidence Rate globally with key countries

        5.4. Regulatory Scenario by Region/globally

    6. Global Arthritis Therapeutics Market Analysis and Forecast, By Type 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

            6.3.1. Rheumatoid Arthritis

            6.3.2. Osteoarthritis

            6.3.3. Psoriatic Arthritis

            6.3.4. Gout

            6.3.5. Others

        6.4. Market Attractiveness By Type

    7. Global Arthritis Therapeutics Market Analysis and Forecast, By Drug Class 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

            7.3.1. TNF Inhibitors

            7.3.2. Interleukin Inhibitors

            7.3.3. NSAIDs

            7.3.4. Corticosteroids

            7.3.5. Xanthine Oxidase Inhibitors

            7.3.6. Others

        7.4. Market Attractiveness By Drug Class 

    8. Global Arthritis Therapeutics Market Analysis and Forecast, By Route of Administration 

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

            8.3.1. Oral

            8.3.2. Parenteral

            8.3.3. Topical 

        8.4. Market Attractiveness By Route of Administration 

    9. Global Arthritis Therapeutics Market Analysis and Forecast, By Distribution Channel 

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Attractiveness By Distribution Channel

    10. Global Arthritis Therapeutics Market Analysis and Forecast, By Region 

        10.1. Key Findings

        10.2. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Region

            10.2.1. North America

            10.2.2. Europe 

            10.2.3. Asia Pacific

            10.2.4. Latin America 

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Country/Sub-region /Region

    11. North America Arthritis Therapeutics Market Analysis and Forecast

        11.1.  Introduction

            11.1.1.  Key Findings

        11.2. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

            11.2.1. Rheumatoid Arthritis

            11.2.2. Osteoarthritis

            11.2.3. Psoriatic Arthritis

            11.2.4. Gout

            11.2.5. Others

        11.3.  North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

            11.3.1. TNF Inhibitors

            11.3.2. Interleukin Inhibitors

            11.3.3. NSAIDs

            11.3.4. Corticosteroids

            11.3.5. Xanthine Oxidase Inhibitors

            11.3.6. Others

        11.4.  North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

            11.4.1. Oral

            11.4.2. Parenteral

            11.4.3. Topical 

        11.5. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            11.6.1. U.S.

            11.6.2. Canada

        11.7. North America Market Attractiveness Analysis

            11.7.1. By Type

            11.7.2. By Drug Class

            11.7.3. By Route of Administration

            11.7.4. By Distribution Channel

            11.7.5. By Country/Sub-region 

    12. Europe Arthritis Therapeutics Market Analysis and Forecast

        12.1.  Introduction

            12.1.1.  Key Findings

        12.2. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

            12.2.1. Rheumatoid Arthritis

            12.2.2. Osteoarthritis

            12.2.3. Psoriatic Arthritis

            12.2.4. Gout

            12.2.5. Others

        12.3.  Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

            12.3.1. TNF Inhibitors

            12.3.2. Interleukin Inhibitors

            12.3.3. NSAIDs

            12.3.4. Corticosteroids

            12.3.5. Xanthine Oxidase Inhibitors

            12.3.6. Others

        12.4.  Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

            12.4.1. Oral

            12.4.2. Parenteral

            12.4.3. Topical 

        12.5. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Country/Sub-region, 2017–2027

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Europe Market Attractiveness Analysis

            12.7.1. By Type

            12.7.2. By Drug Class

            12.7.3. By Route of Administration

            12.7.4. By Distribution Channel

            12.7.5. By Country/Sub-region 

    13. Asia Pacific Arthritis Therapeutics Market Analysis and Forecast

        13.1.  Introduction

            13.1.1.  Key Findings

        13.2. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

            13.2.1. Rheumatoid Arthritis

            13.2.2. Osteoarthritis

            13.2.3. Psoriatic Arthritis

            13.2.4. Gout

            13.2.5. Others

        13.3.  Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

            13.3.1. TNF Inhibitors

            13.3.2. Interleukin Inhibitors

            13.3.3. NSAIDs

            13.3.4. Corticosteroids

            13.3.5. Xanthine Oxidase Inhibitors

            13.3.6. Others

        13.4.  Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

            13.4.1. Oral

            13.4.2. Parenteral

            13.4.3. Topical 

        13.5. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Pharmacies

        13.6. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Asia Pacific Market Attractiveness Analysis

            13.7.1. By Type

            13.7.2. By Drug Class

            13.7.3. By Route of Administration

            13.7.4. By Distribution Channel

            13.7.5. By Country/Sub-region 

    14. Latin America Arthritis Therapeutics Market Analysis and Forecast

        14.1.  Introduction

            14.1.1.  Key Findings

        14.2. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

            14.2.1. Rheumatoid Arthritis

            14.2.2. Osteoarthritis

            14.2.3. Psoriatic Arthritis

            14.2.4. Gout

            14.2.5. Others

        14.3. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

            14.3.1. TNF Inhibitors

            14.3.2. Interleukin Inhibitors

            14.3.3. NSAIDs

            14.3.4. Corticosteroids

            14.3.5. Xanthine Oxidase Inhibitors

            14.3.6. Others

        14.4.  Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

            14.4.1. Oral

            14.4.2. Parenteral

            14.4.3. Topical 

        14.5. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Pharmacies

        14.6. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Latin America Market Attractiveness Analysis

            14.7.1. By Type

            14.7.2. By Drug Class

            14.7.3. By Route of Administration

            14.7.4. By Distribution Channel

            14.7.5. By Country/Sub-region 

    15. Middle East & Africa Arthritis Therapeutics Market Analysis and Forecast

        15.1.  Introduction

            15.1.1.  Key Findings

        15.2. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

            15.2.1. Rheumatoid Arthritis

            15.2.2. Osteoarthritis

            15.2.3. Psoriatic Arthritis

            15.2.4. Gout

            15.2.5. Others

        15.3.  Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

            15.3.1. TNF Inhibitors

            15.3.2. Interleukin Inhibitors

            15.3.3. NSAIDs

            15.3.4. Corticosteroids

            15.3.5. Xanthine Oxidase Inhibitors

            15.3.6. Others

        15.4.  Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

            15.4.1. Oral

            15.4.2. Parenteral

            15.4.3. Topical 

        15.5. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

            15.5.1. Hospital Pharmacies

            15.5.2. Retail Pharmacies

            15.5.3. Online Pharmacies

        15.6. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Middle East & Africa Market Attractiveness Analysis

            15.7.1. By Type

            15.7.2. By Drug Class

            15.7.3. By Route of Administration

            15.7.4. By Distribution Channel

            15.7.5. By Country/Sub-region 

    16. Competition Landscape

        16.1. Market Share Analysis By Company (2018)

        16.2.  Company Profiles

            16.2.1. Novartis AG

                16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.1.2. Financial Overview      

                16.2.1.3. Product Portfolio

                16.2.1.4. Strategic Overview

                16.2.1.5. SWOT Analysis

            16.2.2. Eli Lilly and Company

                16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.2.2. Financial Overview      

                16.2.2.3. Product Portfolio

                16.2.2.4. Strategic Overview

                16.2.2.5. SWOT Analysis

            16.2.3. Amgen, Inc.

                16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.3.2. Financial Overview      

                16.2.3.3. Product Portfolio

                16.2.3.4. Strategic Overview

                16.2.3.5. SWOT Analysis

            16.2.4. Merck & Co., Inc.

                16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.4.2. Financial Overview      

                16.2.4.3. Product Portfolio

                16.2.4.4. Strategic Overview

                16.2.4.5. SWOT Analysis

            16.2.5. Bristol-Myers Squibb Company

                16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.5.2. Financial Overview      

                16.2.5.3. Product Portfolio

                16.2.5.4. Strategic Overview

                16.2.5.5. SWOT Analysis

            16.2.6. Pfizer, Inc. 

                16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.6.2. Financial Overview      

                16.2.6.3. Product Portfolio

                16.2.6.4. Strategic Overview

                16.2.6.5. SWOT Analysis

            16.2.7. AbbVie, Inc.

                16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.7.2. Financial Overview      

                16.2.7.3. Product Portfolio

                16.2.7.4. Strategic Overview

                16.2.7.5. SWOT Analysis

            16.2.8. Janssen Global Services, LLC (Johnson & Johnson)

                16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.8.2. Financial Overview      

                16.2.8.3. Product Portfolio

                16.2.8.4. Strategic Overview

                16.2.8.5. SWOT Analysis

            16.2.9. F. Hoffmann-La Roche Ltd

                16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.9.2. Financial Overview      

                16.2.9.3. Product Portfolio

                16.2.9.4. Strategic Overview

                16.2.9.5. SWOT Analysis

            16.2.10. Sanofi

                16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.10.2. Financial Overview      

                16.2.10.3. Product Portfolio

                16.2.10.4. Strategic Overview

                16.2.10.5. SWOT Analysis

    List of Tables

    Table 01: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 02: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 03: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 04: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 05: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 06: North America Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 07: North America Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 08: North America Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration,

    Table 09: North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 10: North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027

    Table 11: Europe Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 12: Europe Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 13: Europe Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 14: Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 15: Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

    Table 16: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 17: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 18: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 19: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 20: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

    Table 21: Latin America Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 22: Latin America Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 23: Latin America Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 24: Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 25: Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

    Table 26: Middle East & Africa Arthritis Therapeutics Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 27: Middle East & Africa Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 28: Middle East & Africa Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 29: Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 30: Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017–2027

    List of Figures

    Figure 01: Global Arthritis Therapeutics Market Snapshot

    Figure 02: Global Arthritis Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 03: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2017?2027

    Figure 04: Global Arthritis Therapeutics Market Value Share (%), by Type (2018)

    Figure 05: Global Arthritis Therapeutics Market Value Share (%), by Route of Administration (2018)

    Figure 06: Global Arthritis Therapeutics Market Value Share (%), by Drug Class (2018)

    Figure 07: Global Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2018)

    Figure 08: Global Arthritis Therapeutics Market Value Share (%), by Region (2018)

    Figure 09: Global Arthritis Therapeutics Market Value Share Analysis, by Type, 2018 and 2027

    Figure 10: Global Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

    Figure 11: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Rheumatoid Arthritis, 2017–2027

    Figure 12: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Osteoarthritis, 2017–2027

    Figure 13: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Psoriatic Arthritis, 2017–2027

    Figure 14: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gout, 2017–2027

    Figure 15: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

    Figure 16: Global Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 17: Global Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 18: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017–2027

    Figure 19: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2017–2027

    Figure 20: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by NSAIDs, 2017–2027

    Figure 21: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017–2027

    Figure 22: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Xanthine Oxidase Inhibitors, 2017–2027

    Figure 23: Global Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

    Figure 24: Global Arthritis Therapeutics Market Value Share(%), by Route of Administration, 2018 and 2027

    Figure 25: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2017–2027

    Figure 26: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2017–2027

    Figure 27: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2017–2027

    Figure 28: Global Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 29: Global Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 30: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017–2027

    Figure 31: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017–2027

    Figure 32: Global Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017–2027

    Figure 33: Global Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 34: Global Arthritis Therapeutics Market Value Share Analysis, by Region 2018 and 2027

    Figure 35: Global Arthritis Therapeutics Market Attractiveness, by Region, 2019–2027

    Figure 36: North America Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 37: North America Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

    Figure 38: North America Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

    Figure 39: North America Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

    Figure 40: North America Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 41: North America Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

    Figure 42: North America Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 43: North America Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 44: North America Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 45 : North America Arthritis Therapeutics Market Value Share (%), By Country/Sub-region , 2018 and 2027

    Figure 46: North America Arthritis Therapeutics Market Attractiveness, By Country/Sub-region , 2019–2027

    Figure 47: Europe Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 48: Europe Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

    Figure 49: Europe Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

    Figure 50: Europe Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

    Figure 51: Europe Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 52: Europe Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

    Figure 53: Europe Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 54: Europe Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 55: Europe Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 56: Europe Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

    Figure 57: Europe Arthritis Therapeutics Market Attractiveness, By Country/Sub-region /Sub-region, 2019–2027

    Figure 58: Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 59: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

    Figure 60: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

    Figure 61: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

    Figure 62: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 63: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

    Figure 64: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 65: Asia Pacific Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 66: Asia Pacific Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 67 : Asia Pacific Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

    Figure 68: Asia Pacific Arthritis Therapeutics Market Attractiveness, By Country/Sub-region /Sub-region, 2019–2027

    Figure 69: Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 70: Latin America Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

    Figure 71: Latin America Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

    Figure 72: Latin America Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

    Figure 73: Latin America Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 74: Latin America Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

    Figure 75: Latin America Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 76: Latin America Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 77: Latin America Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 78 : Latin America Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

    Figure 79: Latin America Arthritis Therapeutics Market Attractiveness, By Country/Sub-region /Sub-region, 2019–2027

    Figure 80: Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 81: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Type, 2018 and 2027

    Figure 82: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Type, 2019–2027

    Figure 83: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2027

    Figure 84: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 85: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

    Figure 86: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 87: Middle East & Africa Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 88: Middle East & Africa Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 89: Middle East & Africa Arthritis Therapeutics Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027

Copyright © Transparency Market Research, Inc. All Rights reserved